<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175926</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/15</org_study_id>
    <nct_id>NCT03175926</nct_id>
  </id_info>
  <brief_title>Description of the Ability to Learn How to Handle Inhaler Devices in Asthma</brief_title>
  <acronym>AUDIT</acronym>
  <official_title>Description of the Ability to Learn How to Handle Inhaler Devices in Asthma - AUDIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a major public health problem. The main treatments against asthma are delivered to
      the lung through several dry-powder inhaler such as Turbuhaler ®, Diskus® and the new
      Ellipta® device. In real life, patient's ability to handle a device is not routinely assessed
      by their practitioner. We hypothesized that many asthmatics cannot properly prepare and prime
      their device, which may alter the positive effects observed in clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to describe the handling of inhaler devices (Diskus®,
      Turbuhaler® and Ellipta®) in patients with asthma.

      All participants will use each inhaler device (Diskus®, Turbuhaler® and Ellipta®) daily for
      one week:

        -  Two puffs per day (Diskus® and Turbuhaler®),

        -  One puff per day (Ellipta®). At each visit (day 1, 8, 15 and 22), patients will have a
           physical exam.

      For each inhaler device, 4 video recordings will be performed:

        -  Video recording #1: Inhalation (one puff) without any instruction of use.

        -  Video recording #2: Inhalation (one puff) after reading the patient information leaflet.

        -  Video recording #3: Inhalation (one puff) after watching a standardized video
           demonstrating correct inhaler technique.

        -  Video recording #4: inhalation (one puff) after seven days of daily use. The patient
           will be asked to fulfill a satisfaction survey about each inhaler device.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Critical errors</measure>
    <time_frame>Day 8 of each treatment</time_frame>
    <description>Assessment of the presence of at least a critical error in the use of the inhalation system, from standardized checklist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non device-dependent errors</measure>
    <time_frame>Day 8 of each treatment</time_frame>
    <description>Assessment of the presence of non device-dependent errors from standardized checklist with first device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for drug administration</measure>
    <time_frame>Day 8 of each treatment</time_frame>
    <description>Measure of the necessary time for drug administration with each device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction questionnaire</measure>
    <time_frame>Day 8 of each treatment</time_frame>
    <description>Questionnaire of satisfaction about the use of each device</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo Diskus®</intervention_name>
    <description>device will be given daily for one week, two puffs per day</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo Ellipta®</intervention_name>
    <description>device will be given daily for one week, one puff per day</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulmicort® Turbuhaler®</intervention_name>
    <description>device will be given daily for one week, two puffs per day</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged more than 18 years

          -  Written informed consent

          -  Diagnosis of asthma according to international guidelines (GINA 2017)

          -  Social security or health insurance

          -  Women using an effective method of birth control.

        Exclusion Criteria:

          -  Previous treatment with Ellipta®, Diskus® or Turbuhaler®

          -  Asthma exacerbation within 6 weeks before inclusion

          -  Subject having close contacts with devices (Ellipta®, Diskus® or Turbuhaler®) users,
             currently or in the past

          -  Severe asthma

          -  Hypersensitivity to budesonide

          -  Chronic psychiatric disease

          -  Medical condition that may affect handling of inhaler devices

          -  Subject deprived of his/her liberty

          -  Protected adult

          -  Subject in exclusion period related to another protocol

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Olivier GIRODET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Olivier GIRODET, MD</last_name>
    <phone>+33 (0)5 57 62 31 94</phone>
    <email>pierre-olivier.girodet@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Olivier GIRODET, MD</last_name>
      <phone>+33 (0)5 57 62 31 94</phone>
      <email>pierre-olivier.girodet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie NIEL</last_name>
      <phone>+33 (0)5 57 62 31 94</phone>
      <email>virginie.niel@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Olivier GIRODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>inhaler device</keyword>
  <keyword>handling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

